Stock Events

Medigene 

€1.16
1
+€0+0% Wednesday 08:47

Statistics

Day High
1.16
Day Low
1.16
52W High
2.25
52W Low
1.16
Volume
14
Avg. Volume
128
Mkt Cap
449,394
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Earnings

15AugExpected
Q2 2022
Q3 2022
Q1 2023
Q2 2023
Q3 2023
Q1 2024
Next
-0.95
-0.9
-0.86
-0.81
Expected EPS
N/A
Actual EPS
N/A

People Also Follow

This list is based on the watchlists of people on Stock Events who follow 0QGJ.LSE. It's not an investment recommendation.

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.

About

Medigene AG, a biotechnology company, focuses on the development of T cell immunotherapies for the treatment of cancer. The company is developing personalized T cell-based therapies with a focus on T cell receptor-modified T cells in the areas of unmet medical needs, which are in clinical development. It also focuses on dendritic cell vaccines and T cell-specific monoclonal antibodies. In addition, the company focuses on developing and marketing RhuDex for hepatology and gastroenterology indications. Medigene AG has a strategic partnership with 2seventy bio, Inc. for the development of T cell receptors. The company also has research collaboration agreements on novel cancer antigens for immunotherapies with the Université de Montréal; and with Cytovant Sciences Co. Ltd. It has operations in Europe, the United States, Asia, and internationally. The company was founded in 1994 and is headquartered in Munich, Germany.
Show more...
CEO
Dr. Dolores J. Schendel
Employees
58
Country
DE
ISIN
DE000A1X3W00
WKN
000A1X3W0

Listings